Area of research
Oncology · Immunology
Research interest
Research interests include Medicine, Durvalumab, PARP inhibitor, Olaparib, Ovarian cancer, and Head and neck cancer.
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK
Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile